Yawei Wang1, Haiyan Zhang2, Jing Hao1, Bei Li1, Ming Li1, Wang Xiuwen1. 1. a Department of Chemotherapy , Cancer Center, Qilu Hospital, Shandong University , Ji'nan , P.R. China and. 2. b Department of Otorhinolaryngology Head and Neck Surgery , Provincial Hospital affiliated to Shandong University , Ji'nan , P.R. China.
Abstract
CONTEXT: Paclitaxel (PTX) and doxorubicin (DOX) are widely used for the combined chemotherapy of solid tumors. However, free drug combination has lower antitumor efficiency. It is necessary to design a drug delivery system to carry both of them. OBJECTIVE: This study aimed to engineer a nano-drug delivery system for co-encapsulating PTX and DOX. This system was expected to resolve the multidrug resistance caused by single drug, and the dual-drug-loaded nanostructured lipid carriers were also planned to specifically target the cancer cells without obvious influence on normal cells and tissues. METHODS: In this paper, nanostructured lipid carriers for combination delivery of PTX and DOX were prepared by the melt-emulsification technique. In vitro cytotoxicity against NCL-H460 human non-small cell lung carcinoma (NSCLS) cell line was investigated, and in vivo anti-tumor of NLC was evaluated on mice models grafting NCL-H460 cells. RESULTS: PTX-DOX NLC achieved the highest cytotoxic effect among all formulations in vitro, as compared to single drug delivery NLC. In vivo investigation on NSCLC animal models showed that co-delivery of PTX and DOX possessed high tumor-targeting capacity and strong anti-tumor activity. CONCLUSION: The PTX-DOX NLC constructed in this research offers an effective strategy for targeted combinational lung cancer therapy.
CONTEXT: Paclitaxel (PTX) and doxorubicin (DOX) are widely used for the combined chemotherapy of solid tumors. However, free drug combination has lower antitumor efficiency. It is necessary to design a drug delivery system to carry both of them. OBJECTIVE: This study aimed to engineer a nano-drug delivery system for co-encapsulating PTX and DOX. This system was expected to resolve the multidrug resistance caused by single drug, and the dual-drug-loaded nanostructured lipid carriers were also planned to specifically target the cancer cells without obvious influence on normal cells and tissues. METHODS: In this paper, nanostructured lipid carriers for combination delivery of PTX and DOX were prepared by the melt-emulsification technique. In vitro cytotoxicity against NCL-H460 human non-small cell lung carcinoma (NSCLS) cell line was investigated, and in vivo anti-tumor of NLC was evaluated on mice models grafting NCL-H460 cells. RESULTS:PTX-DOX NLC achieved the highest cytotoxic effect among all formulations in vitro, as compared to single drug delivery NLC. In vivo investigation on NSCLC animal models showed that co-delivery of PTX and DOX possessed high tumor-targeting capacity and strong anti-tumor activity. CONCLUSION: The PTX-DOX NLC constructed in this research offers an effective strategy for targeted combinational lung cancer therapy.
Authors: Consolación Melguizo; Laura Cabeza; Jose Prados; Raúl Ortiz; Octavio Caba; Ana R Rama; Ángel V Delgado; José L Arias Journal: Drug Des Devel Ther Date: 2015-12-14 Impact factor: 4.162
Authors: Thangirala Sudha; Dhruba J Bharali; Murat Yalcin; Noureldien He Darwish; Melis Debreli Coskun; Kelly A Keating; Hung-Yun Lin; Paul J Davis; Shaker A Mousa Journal: Int J Nanomedicine Date: 2017-02-15